Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Cash (2016 - 2025)

Historic Change in Cash for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $5.1 million.

  • Enanta Pharmaceuticals' Change in Cash fell 8909.29% to $5.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$47.5 million, marking a year-over-year decrease of 20698.85%. This contributed to the annual value of -$5.5 million for FY2025, which is 8848.93% up from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Change in Cash is $5.1 million, which was down 8909.29% from -$12.5 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year Change in Cash high stood at $52.6 million for Q3 2021, and its period low was -$72.5 million during Q2 2021.
  • Over the past 5 years, Enanta Pharmaceuticals' median Change in Cash value was -$156500.0 (recorded in 2022), while the average stood at -$745300.0.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Change in Cash soared by 51343.13% in 2021, and later crashed by 246662.9% in 2023.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Change in Cash stood at $41.9 million in 2021, then tumbled by 104.23% to -$1.8 million in 2022, then plummeted by 2466.63% to -$45.5 million in 2023, then soared by 203.65% to $47.1 million in 2024, then crashed by 89.09% to $5.1 million in 2025.
  • Its Change in Cash stands at $5.1 million for Q4 2025, versus -$12.5 million for Q3 2025 and -$15.4 million for Q2 2025.